Human Health
U of T Engineering is a leader in health care engineering. Together with doctors, medical researchers, policymakers and industry, we are helping people around the world live longer, healthier lives.
To enable future success in the evolving bioproducts industry, we developed specialized programs to teach students to translate their bioengineeiring research into successful startups.

- Brain-Machine Interfacing
- Cell Manufacturing
- Disease Modeling & Therapeutics
- Health-care Engineering
- Heart Research
- Next-generation Medical Devices
- Regenerative Medicine
- Synthetic Biology
Medicine by Design undertakes transformative research in regenerative medicine and cell therapy.
Translational Biology and Engineering Program
TBEP drives research at the interface of engineering and medicine. With a roster of multidisciplinary investigators, researchers develop strategies that will repair or regenerate heart muscle.
Centre for Healthcare Engineering
CHE is a leader in interdisciplinary research and education in healthcare engineering. Its research directly impacts healthcare organizations and partners in practice.
Southern Ontario Centre for Atmospheric Aerosol Research
SOCAAR is a world-class centre for environmental research committed to innovation in producing a broad, trans-disciplinary and actionable understanding of the origins, characteristics, environmental impact, and human health consequences of atmospheric aerosols.
Study Human Health at U of T Engineering
The Institute of Biomaterials & Biomedical Engineering (IBBME) — a multidisciplinary research community of engineering, medicine and dentistry investigators — offers research-based graduate programs at both the Master’s and Doctoral levels, as well as a Master of Health Science (MHSc) in Clinical Engineering and a Master of Engineering (MEng) that focuses on the design of biomedical devices. At the undergraduate level, engineering students can minor in Biomedical Engineering or Bioengineering, and Engineering Science students can major in Biomedical Systems Engineering.
Leading innovation starts here
Connect with our partnerships team to discuss how a partnership with U of T Engineering can benefit your organization.

U of T Engineering researchers are working to enable a future where a single, non-invasive injection under the eyelid could replace months of daily eye drops in treating glaucoma, a leading cause of blindness.
In a recently published paper in Advanced Materials, a team led by Professor Molly Shoichet (ChemE, BME) describes how they used colloidal drug aggregates (CDAs) to modify the effects of a small-molecule glaucoma drug.
This new approach prolongs the drug’s effect from six hours when it is delivered via an eye drop, to up to seven weeks with a single, non-invasive injection placed in the subconjunctival space, that is, under the eye lid.
Glaucoma is a group of eye diseases characterized by an increase in eye pressure, leading to damage of the optic nerve, which is essential for vision